LiquidHALLMARK® is a sensitive next-generation sequencing assay targeting both circulating DNA and RNA to profile a patient’s unique cancer. LiquidHALLMARK profiles ctDNA mutations in 80 genes, fusions in 10 genes, and somatic variants. As an add-on option, LiquidHALLMARK analyses 27 ctRNA targets for actionable and emerging fusions.
|
Genes* |
||||||
|---|---|---|---|---|---|---|
| ABL1 | CCND2 # | FBXW7 # | IDH1 | MED12 | PDGFRA # | RIT1 |
| AKT1 | CDH1 | FGFR1 | IDH2 | MET # | PIK3CA # | ROS1 |
| ALK # | CDK6 # | FGFR2 | JAK1 | MLH1 | PIK3R1 | SF3B1 |
| APC | CDKN2A # | FGFR3 | JAK2 | MTOR | PPP2R1A | SMAD4 ^ |
| AR | CREBBP | FLT3 | JAK3 | MYC # | PTEN # | SMO |
| ARAF | CTNNB1 | GATA3 | KEAP1 1 | NF1 | PTPN11 | SPOP |
| ATM | EGFR †# | GNA11 | KIT # | NFE2L2 | RAF1 | STK11 |
| BRAF | ERBB2 # (HER2) | GNAQ | KRAS # | NOTCH1 | RB1 | TERT Promoter |
| BRCA1 #1 | ERCC2 | GNAS | MAP2K1 (MEK1) | NRAS # | RET | TP53 ^ |
| BRCA2 #2 | ESR1 | HNF1A | MAP2K2 (MEK2) | NTRK1 | RHEB | U2AF1 |
| CCND1 # | EZH2 | HRAS | MAPK1 (ERK2) | NTRK3 | RHOA | VHL |
|
Fusions |
||||||
| ALK | AR R (AR-V7 SV) | BRAF R | CTNNB1–PLAG1 R | EGFR R | ERBB4 R | ERG R |
| ESR1 R | ETV1 R | ETV4 R | ETV5 R | FGFR1 R | FGFR2 | FGFR3 |
| FLI1 R | MET (+Ex14 Skipping) | MYB–NFIB R | NRG1 R | NTRK1/2/3 | PAX3–FOXO1 R | PAX8–PPARG R |
| PD–L1 D (CD274) | RET | ROS1 | SSX1 R | SSX2 R | TMPRSS2 D | |
|
Microsatellite Instability (MSI) |
||||||
| BAT25 | BAT26 | NR21 | NR24 | NR27 | MONO27 | |
* Targeted regions selected to maximize detection of known hotspot mutations. # Includes detection of gene copy number changes. † Includes sequencing of EGFR kinase and extracellular domain mutations. ^ Full coverage. 1 >99% coverage. 2 >98.4% coverage of coding exons. R Fusions analysed by ctRNA only. D Fusions analysed by ctDNA only. SV Splice Variant
Fusions highlighted in orange are analyzed using both ctDNA and ctRNA. ctRNA results are currently investigational – results provided for informational, non-diagnostic purposes only.